AKYA Quote, Financials, Valuation and Earnings

Bionano Genomics has a net margin of -55.99% compared to Akoya Biosciences's net margin of -728.57%. Akoya Biosciences's return on equity of -157.22% beat Bionano Genomics's return on equity of -158.95%.

Akoya Biosciences has a consensus price target of $3.48, signalling upside risk potential of 130.46%. On the other hand Bionano Genomics has an analysts' consensus of -- which suggests that it could grow by 1629.1%. Given that Bionano Genomics has higher upside potential than Akoya Biosciences, analysts believe Bionano Genomics is more attractive than Akoya Biosciences.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.247, suggesting its more volatile than the S&P 500 by 124.652%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akoya Biosciences pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Akoya Biosciences quarterly revenues are $18.8M, which are larger than Bionano Genomics quarterly revenues of $6.1M. Akoya Biosciences's net income of -$10.5M is higher than Bionano Genomics's net income of -$44.2M. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.86x versus 0.08x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -55.99% compared to Akoya Biosciences's net margin of 1.4%. Akoya Biosciences's return on equity of -157.22% beat Bruker's return on equity of 6.78%.

Akoya Biosciences has a consensus price target of $3.48, signalling upside risk potential of 130.46%. On the other hand Bruker has an analysts' consensus of $68.42 which suggests that it could grow by 48.86%. Given that Akoya Biosciences has higher upside potential than Bruker, analysts believe Akoya Biosciences is more attractive than Bruker.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.406%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.44% to investors and pays a quarterly dividend of $0.05 per share. Akoya Biosciences pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Akoya Biosciences quarterly revenues are $18.8M, which are smaller than Bruker quarterly revenues of $979.6M. Akoya Biosciences's net income of -$10.5M is lower than Bruker's net income of $13.7M. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Bruker's PE ratio is 60.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.86x versus 2.04x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -55.99% compared to Akoya Biosciences's net margin of 0.07%. Akoya Biosciences's return on equity of -157.22% beat Harvard Bioscience's return on equity of -18.36%.

Akoya Biosciences has a consensus price target of $3.48, signalling upside risk potential of 130.46%. On the other hand Harvard Bioscience has an analysts' consensus of $4.25 which suggests that it could grow by 555.97%. Given that Harvard Bioscience has higher upside potential than Akoya Biosciences, analysts believe Harvard Bioscience is more attractive than Akoya Biosciences.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.371%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akoya Biosciences pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Akoya Biosciences quarterly revenues are $18.8M, which are smaller than Harvard Bioscience quarterly revenues of $24.6M. Akoya Biosciences's net income of -$10.5M is lower than Harvard Bioscience's net income of $18K. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.86x versus 0.30x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -55.99% compared to Akoya Biosciences's net margin of -23.59%. Akoya Biosciences's return on equity of -157.22% beat Quanterix's return on equity of -10.38%.

Akoya Biosciences has a consensus price target of $3.48, signalling upside risk potential of 130.46%. On the other hand Quanterix has an analysts' consensus of $19.75 which suggests that it could grow by 179.75%. Given that Quanterix has higher upside potential than Akoya Biosciences, analysts believe Quanterix is more attractive than Akoya Biosciences.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Quanterix has a beta of 1.336, suggesting its more volatile than the S&P 500 by 33.57%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akoya Biosciences pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Akoya Biosciences quarterly revenues are $18.8M, which are smaller than Quanterix quarterly revenues of $35.4M. Akoya Biosciences's net income of -$10.5M is lower than Quanterix's net income of -$8.4M. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.86x versus 2.04x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.